Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01440985
Other study ID # A6431085
Secondary ID 2005-001040-23
Status Completed
Phase N/A
First received September 23, 2011
Last updated July 6, 2012
Start date July 2005
Est. completion date November 2005

Study information

Verified date July 2012
Source Johnson & Johnson Consumer and Personal Products Worldwide
Contact n/a
Is FDA regulated No
Health authority Ireland: Irish Medicines Board
Study type Interventional

Clinical Trial Summary

Participants will be smokers who want to quit, and have visible nicotine stains on their teeth. They will be given toothpaste and a toothbrush to use during the study, and will have an equal chance of being assigned to use either a nicotine gum or microtab. They will visit the study site five times during the 12 week trial to have their teeth examined.


Description:

This evaluator-blinded, randomized, 12-week parallel-group controlled trial compares Nicorette® Freshmint gum versus Nicorette® Microtab in healthy smokers who are motivated to quit smoking and who have visible staining of teeth.

The trial is comprised of five visits (baseline, Weeks 1, 2, 6, and 12). At baseline, subjects will be provided with a standardized toothpaste and toothbrush; use of any other oral hygiene or tooth-whitening product is prohibited. At all visits after baseline, smoking status and use of study treatment will be checked. Teeth staining and teeth shade will be rated at baseline and at 2, 6 and 12 Weeks using the Modified Lobene Stain Index and the Vita® Shade Guide, respectively.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date November 2005
Est. primary completion date November 2005
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Males and females aged 18 to 65 years

- Daily smoker, current daily smoking for at least 1 year

- Motivated to quit smoking, and willing to use NRT (nicotine gum or nicotine sublingual tablet)

- Normal chewing abilities (able to use chewing gum without any problems)

- Willing to refrain from dental prophylaxis for the duration of the 12-week trial

- Have a minimum of 20 natural teeth, with at least 10 of the 12 anterior teeth present and scorable.

- Have a total extrinsic facial tooth stain score equal or more than 28, according to the MacPherson Modification of the Lobene Stain Index.

- Willing and able to comply with scheduled visits, treatment plan, tests, and other trial procedures.

Exclusion Criteria:

- Use of other tobacco-containing products, such as cigars, pipe, smokeless tobacco products, etc.

- Existing use of any nicotine replacement products for smoking cessation, or undergoing any other treatment for tobacco dependence, such as hypnosis, acupuncture, bupropion, etc.

- Orthodontic appliances

- Gross periodontal disease, or signs of gross oral neglect

- History of oral cancer

- History of temporomandibular joint disorders known to aggravate jaw pain

- Unstable angina pectoris or myocardial infarction during the previous 3 months

- Pregnancy, lactation or intended pregnancy

- Any major metabolic disease, clinically important renal or hepatic disease Suspected alcohol or drug abuse

- Participation in another clinical trial within the previous three months and during study participation

- Any other severe acute or chronic medical or psychiatric condition that might increase the risk associated with trial participation or trial drug administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, makes the subject inappropriate for entry into this trial.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)


Related Conditions & MeSH terms


Intervention

Drug:
Nicotine
Nicotine Gum 2 mg, Lot number GD922A
Nicotine
Nicotine gum 4 mg, Lot number GC962A
Nicotine
Nicotine Microtab 2 mg, Lot number GB196G

Locations

Country Name City State
Ireland Dental School and Hospital, University College of Cork Wilton Cork

Sponsors (1)

Lead Sponsor Collaborator
McNeil AB

Country where clinical trial is conducted

Ireland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline in Total Extrinsic Tooth Stain Score Mean change in total extrinsic tooth stain score, for the whole mouth region. Extrinsic tooth staining is measured using the MacPherson Modification of the Lobene Stain Index. A lower stain index score represents a reduction in extrinsic tooth staining. Baseline, 6 Weeks No
Secondary Change from Baseline in Total Extrinsic Tooth Stain Score Mean change in total extrinsic tooth stain score, for the whole mouth region, measured using the MacPherson Modification of the Lobene Stain Index. A lower stain index score represents a reduction in extrinsic tooth staining. Baseline, 2 Weeks No
Secondary Change from Baseline in Total Extrinsic Tooth Stain Score Mean change in total extrinsic tooth stain score, for the whole mouth region, measured using the MacPherson Modification of the Lobene Stain Index. A lower stain index score represents a reduction in extrinsic tooth staining. Baseline, 12 Weeks No
Secondary Change from Baseline in Mean Stain Index Facial Region Mean changes in the extrinsic facial surface stain score between baseline and Weeks 2, 6 and 12. Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Index Lingual Region Mean changes in the extrinsic lingual surface stain score between baseline and 2, 6 and 12 weeks. Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Index Body Region Mean changes in the extrinsic body region stain scores between baseline and 2, 6 and 12 weeks. Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Index Gingival Region Mean changes in the extrinsic gingival region stain scores between baseline and 2, 6 and 12 weeks. Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Index Interproximal Region Mean changes in the extrinsic interproximal region stain scores between baseline and 2, 6 and 12 weeks. Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Area Total Region Mean stain area between baseline and Weeks 2, 6 and 12 for the facial region, lingual region, body region, gingival region, and interproximal region (Total Region). Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Area Facial Region Mean stain area between baseline and Weeks 2, 6 and 12 for the facial region. Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Area Lingual Region Mean stain area between baseline and Weeks 2, 6 and 12 for the lingual region. Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Area Body Region Mean stain area between baseline and Weeks 2, 6 and 12 for the body region. Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Area Gingival Region Mean stain area between baseline and Weeks 2, 6 and 12 for the gingival region. Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Area Interproximal Region Mean stain area between baseline and Weeks 2, 6 and 12 for the interproximal region. Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Intensity Total Region Mean stain intensity between baseline and Weeks 2, 6 and 12 for the facial region, lingual region, body region, gingival region, and interproximal region (Total Region). Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Intensity Facial Region Mean stain intensity between baseline and Weeks 2, 6 and 12 for the facial region. Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Intensity Lingual Region Mean stain intensity between baseline and Weeks 2, 6 and 12 for the lingual region. Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Intensity Body Region Mean stain intensity between baseline and Weeks 2, 6 and 12 for the body region. Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Intensity Gingival Region Mean stain intensity between baseline and Weeks 2, 6 and 12 for the gingival region. Baseline through Week 12 No
Secondary Change from Baseline in Mean Stain Intensity Interproximal Region Mean stain intensity between baseline and Weeks 2, 6 and 12 for the interproximal region. Baseline through Week 12 No
Secondary Change from Baseline in Mean Tooth Shade Mean tooth shade between baseline and Weeks 2, 6, and 12 using the Vita® Shade Guide. A higher number represents a lighter tooth shade. Baseline through Week 12 No
See also
  Status Clinical Trial Phase
Completed NCT01928719 - Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status N/A
Completed NCT01995123 - Behavioral Activation for Smoking Cessation in PTSD N/A
Not yet recruiting NCT03249428 - E-Cigarette Inner City RCT N/A
Recruiting NCT02564289 - Cardiovascular Effects of Chronic Snus Use N/A
Completed NCT01928758 - Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders N/A
Withdrawn NCT01847300 - cSBI-M for Young Military Personnel N/A
Completed NCT01570595 - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV Phase 1/Phase 2
Completed NCT01428310 - Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke Phase 1
Recruiting NCT00977249 - Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users Phase 2/Phase 3
Active, not recruiting NCT00968513 - Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry Phase 3
Completed NCT00747643 - Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement N/A
Completed NCT00722124 - S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence Phase 2/Phase 3
Completed NCT01113424 - Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum N/A
Completed NCT01238627 - Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg N/A
Completed NCT01228617 - Single-dose Pharmacokinetics of Oral Nicotine Replacement Products N/A
Completed NCT00296647 - Smoking Cessation Intervention: Effectiveness in Primary Care Phase 4
Completed NCT00394420 - Emergency Department Telephone Quitline N/A
Recruiting NCT05487807 - Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia Phase 1
Completed NCT03553992 - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers N/A
Withdrawn NCT05440721 - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification N/A